# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first tw...
– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, li...
– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and eff...
- Reuters
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clin...
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem c...
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these i...